[ad_1]
New York, June 7, 2021 (Global News Agency) – Pomerantz LLP is investigating claims on behalf of Travere Therapeutics, Inc. (“Travere” or “Company”) (NASDAQ: TVTX) investors. It is recommended that such investors contact Robert S. Willoughby newaction@pomlaw.com Or 888-476-6529, ext. 7980.
The investigation involves whether Travere and some of its officers and/or directors are engaged in securities fraud or other illegal business practices.
[Click here for information about joining the class action]
On May 25, 2021, Travere issued a press release “Providing[ing] Its regulatory update of the sparsentan program in focal segmental glomerulosclerosis (FSGS). The press release stated, “[i]n Recently received the final pre-NDA meeting minutes. The FDA acknowledged that there is a high demand for approved therapies for the treatment of FSGS, but stated that the data available for the interim evaluation of the DUPLEX study is insufficient to support accelerated approval at this time. Based on this feedback, the company no longer expects Submit the accelerated approval of FSGS in the United States in the second half of 2021. The FDA stated that it may submit an application for accelerated approval after additional data is generated in the study. Based on further discussions with the FDA, the company believes that it is possible to provide sufficient additional estimated glomerular filtration from the DUPLEX study in the first half of 2022 ( eGFR) data. The FDA has encouraged companies to request follow-up meetings to further explore this option in more detail, and is expected to hold a Class A meeting in the third quarter of 2021. ”
Affected by this news, Travere’s stock price plummeted by US$2.36 per share, a decrease of 13.30%, and closed at US$15.39 per share on May 26, 2021.
Pomerantz has offices in New York, Chicago, Los Angeles, and Paris, and is recognized as one of the leading firms in the field of corporate, securities and antitrust litigation. Pomerantz Firm was founded by the late Abraham L. Pomerantz and is known as the president of the Class Litigation Lawyers Association, setting a precedent in the field of securities class actions. Today, more than 80 years later, Pomerantz continues to follow the tradition he founded to fight for the rights of victims of securities fraud, breach of fiduciary duties, and corporate misconduct. The company has recovered millions of dollars in damages on behalf of its members.Look www.pomerantzlaw.com
contact:
Robert S. Willoughby
Pomerantz Law Firm
rswilloughby@pomlaw.com
[ad_2]
Source link
